Bevacizumab-based Chemotherapy for Poorly-differentiated Neuroendocrine Tumors.
Fiche publication
Date publication
octobre 2018
Journal
Anticancer research
Auteurs
Membres identifiés du Cancéropôle Est :
Pr GHIRINGHELLI François, Dr VINCENT Julie, Dr BENGRINE-LEFEVRE Leila, Dr FUMET Jean-David
Tous les auteurs :
Collot T, Fumet JD, Klopfenstein Q, Vincent J, Bengrine L, Ghiringhelli F
Lien Pubmed
Résumé
To assess and report the efficacy of and tolerance to bevacizumab-based chemotherapy in treatment outcome of metastatic poorly differentiated neuroendocrine tumors.
Mots clés
Metastatic poorly differentiated neuroendocrine tumor, bevacizumab, chemotherapy, retrospective study
Référence
Anticancer Res.. 2018 Oct;38(10):5963-5968